Newbury Pharmaceuticals AB (publ)
Stockholm Stock ExchangeTotal Valuation
Newbury Pharmaceuticals AB (publ) carries a market capitalization of 52.88M, placing it among publicly traded companies globally.
| Market Cap | 52.88M |
| Enterprise Value | N/A |
Share Statistics
Newbury Pharmaceuticals AB (publ) currently has 30.40M shares outstanding.
| Shares Outstanding | 30.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 1.22 |
| PB Ratio | N/A |
| P/TBV Ratio | 25.98 |
| P/FCF Ratio | -3.27 |
| P/OCF Ratio | -3.26 |
Financial Position
Newbury Pharmaceuticals AB (publ) maintains a current ratio of 1.12, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.12 |
| Quick Ratio | 0.24 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -21.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.41 |
Stock Price Statistics
Newbury Pharmaceuticals AB (publ)'s stock has declined approximately -31.08108% over the past 52 weeks. The 50-day moving average sits at 1.66, while the 200-day moving average is 1.51.
| Beta (5Y) | N/A |
| 52-Week Price Change | -31.08108% |
| 50-Day Moving Average | 1.66 |
| 200-Day Moving Average | 1.51 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Newbury Pharmaceuticals AB (publ) generated 26.86M in revenue and converted that into -17.67M in net income, yielding earnings per share of -0.62. EBITDA reached -16.43M, while operating income came in at -16.43M.
| Revenue | 26.86M |
| Gross Profit | 8.25M |
| Operating Income | -16.43M |
| Pretax Income | -17.67M |
| Net Income | -17.67M |
| EBITDA | -16.43M |
| EBIT | -16.43M |
| Earnings Per Share (EPS) | -0.62 |
Balance Sheet
| Cash & Cash Equivalents | 10.07M |
| Total Debt | N/A |
| Net Debt | -10.07M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 4.88M |
Cash Flow
Newbury Pharmaceuticals AB (publ) produced -10.08M in operating cash flow over the past twelve months.
| Operating Cash Flow | -10.08M |
| Capital Expenditures | N/A |
| Free Cash Flow | -10.08M |
| FCF Per Share | -0.35 |
Margins
Newbury Pharmaceuticals AB (publ) operates with a gross margin of 30.72, reflecting its pricing power and cost economics. The operating margin of -61.16 and net profit margin of -65.77 provide insight into operational efficiency.
| Gross Margin | 30.72 |
| Operating Margin | -61.16 |
| Pretax Margin | -65.77 |
| Profit Margin | -65.77 |
| EBITDA Margin | -61.16 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -16.37 |
| FCF Yield | -30.60 |
Scores
Newbury Pharmaceuticals AB (publ) posts an Altman Z-Score of -0.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.03 |